Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New rotor device aims to speed up pancreatitis recovery

NCT ID NCT07253350

Disease control Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new device called Endorotor to standard methods for removing dead pancreatic tissue in patients with severe pancreatitis. About 64 adults who need this procedure will be randomly assigned to one of two groups. The goal is to see if the Endorotor clears the tissue faster and with fewer complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Endorotor PED® system (a medical device for removing dead tissue)
What this could lead to
If it works, this could speed up recovery from severe pancreatitis and reduce complications, offering a more effective way to clear dead tissue.
What could go wrong
This is a small early-stage trial (64 people), so results may not apply to everyone. The device may not work better than standard techniques and carries risks like bleeding or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 64 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Nov 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age≥18years * ASA\<5 * CT scan less than 7 days old * Hospitalized for acute necrotizing pancreatitis, whatever the cause, and who have undergone drainage of pancreatic collections for the following indications according to the revised Atlanta criteria (infection, organ compression, persistent organ failure) * Have need for at least one DEN session despite endoscopic drainage (persistence of clinical symptoms or sepsis \>48h after drainage with collection still visible) Exclusion Criteria: * No endoscopic drainage in place for the management of WON * Have already had a DEN session (endoscopic or else) before screening for inclusion * Life-expectancy \< 1year (advanced cancer, etc) * Known haemostasis disorder (chronic thrombocytopenia, haemophilia, etc.) * Pregnant or breastfeeding woman * Subject deprived of freedom, subject under a legal protective measure * Non-affiliation to a social security regimen or CMU * Patient or person of confidence (if present at the time of inclusion) opposing the patient's participation in research * Subject already involved in another interventional clinical research

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute necrotizing pancreatitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute necrotizing pancreatitis Pancreatitis, Acute Necrotizing

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute necrotizing pancreatitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hospital Beaujon, APHP

    RECRUITING

    Clichy, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.